The FDA has approved an updated label for IBTROZI (taletrectinib), a treatment for ROS1-positive non-small cell lung cancer (NSCLC), reflecting a median duration of response of nearly 50 months in TKI-naïve patients from the TRUST-I study. This update confirms long-term clinical benefit and safety with no new safety concerns after extended follow-up. The approval, granted four months ahead of schedule, reinforces IBTROZI as a durable and tolerable treatment option for advanced ROS1+ NSCLC. Nuvation Bio continues to advance global regulatory efforts and ongoing clinical trials for this therapy.
The FDA approval update for IBTROZI® highlights a median duration of response of nearly 50 months in TKI-naïve advanced ROS1-positive non-small cell lung cancer patients. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 18:11 WIB: out of 91 priced US health stocks, 63 rose and 25 fell. Notable movers include Sana Biotechnology Inc (SANA) at USD 3.00 with 86% sell order activity, Twist Bioscience Corp (TWST) at USD 146.86 with nearly balanced buy/sell activity, and BioNano Genomics Inc (BNGO) at USD 1.55 with 77% sell order activity.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
A suspected exploit drained about $75,000 from the WAX multichain bridge that connects WAX, Solana, and Ethereum. The attacker withdrew tokens on WAX without paying corresponding assets, causing the bridge contracts on Solana and Ethereum to release ...
